Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

Completed · Phase 2

Conditions studied: Lymphoma

In brief

The purpose of this study is to assess the clinical benefit of Nivolumab, as measured by independent radiologic review committee (IRRC)-assessed objective response rate (ORR) in subjects with FL lymphoma who have failed therapy with both CD20 antibody and an alkylating agent.

Key facts

Study ID

NCT02038946

Run by

Bristol-Myers Squibb

People needed

116

Starts

2014-03-26

Expected to finish

2020-12-28

Last updated by the study team

2022-01-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Grade 1, 2, or 3a FL without pathologic evidence of transformation
• Male and female, ages 18 and above, with relapsed or refractory FL lymphoma after > or =2 prior treatment lines; each of the 2 prior treatment lines must include at least CD20 antibody and/or an alkylating agent
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1

You may not qualify if…

• Known central nervous system lymphoma
• History of interstitial lung disease
• Subjects with active, known or suspected autoimmune disease
• Prior allogeneic stem cell transplant
• Prior autologous stem cell transplant ≤12 weeks prior to first dose of study drug

Where it is running

• Mayo Clinic Arizona — Phoenix, Arizona, United States
• Division Of Hematology & Oncology Ctr. For Health Sciences — Los Angeles, California, United States
• Winship Cancer Institute. — Atlanta, Georgia, United States
• Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Weill Cornell Medical College — New York, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Huntsman Cancer Institute — Salt Lake City, Utah, United States
• Local Institution — Woodville, South Australia, Australia
• Local Institution — Parkville, Victoria, Australia
• Local Institution — B-leuven, Belgium
• Local Institution — Brussels, Belgium
• Local Institution — Ghent, Belgium
• Jewish General Hospital — Montreal, Quebec, Canada
• CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski — Rimouski, Quebec, Canada
• Local Institution — Créteil, France
• Local Institution — Montpellier, France
• Local Institution — Pierre-Bénite, France
• Local Institution — Rennes, France
• Universitaetsklinikum Essen — Essen, Germany
• Universitaetsklinikum d. Saarlandes — Homburg, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.